[EPZM] Epizyme, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 554.46 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 11.75 Change: 0.05 (0.43%)
Ext. hours: Change: 0 (0%)

chart EPZM

Refresh chart

Strongest Trends Summary For EPZM

EPZM is in the medium-term up 28% in 2 months and up 69% above S&P in 3 months. In the long-term down -25% in 1 year and down -87% below S&P in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops personalized therapeutics for patients with genetically defined cancers. It identifies the genetic alterations that create cancer causing genes, known as oncogenes; selects patients in whom the identified genetic alteration is found; and designs small molecule therapeutic product candidates to inhibit the oncogene. The company has two histone methyltransferases (HMT) inhibitors in clinical development for the treatment of patients with genetically defined cancers. It is conducting a Phase I clinical trial of its product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT for the treatment of acute leukemias with genetic alterations of the MLL gene; and a Phase I/II clinical trial of another product candidate, EPZ-6438, an inhibitor targeting the EZH2 HMT for the treatment of a genetically defined subtype of non-Hodgkin lymphoma and solid tumors, including INI1-deficient tumors, such as synovial sarcoma and malignant rhabdo

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding57.22 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -90.4% Sales Growth - Q/Q-91.2% P/E
P/E To EPS Growth P/S19.17 P/BV2.54 Price/Cash Per Share
Price/Free Cash Flow-14.75 ROA-43.21% ROE-50.12% ROI
Current Ratio20.83 Quick Ratio Long Term Debt/Equity Debt Ratio0.05
Gross Margin Operating Margin-378.54% Net Profit Margin-378.3% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities117.28 M Cash From Investing Activities-40.16 M Cash From Operating Activities-22.71 M Gross Profit
Net Profit-61.33 M Operating Profit-61.38 M Total Assets253.27 M Total Current Assets247.4 M
Total Current Liabilities11.88 M Total Debt1.68 M Total Liabilities34.89 M Total Revenue910 K
Technical Data
High 52 week19.75 Low 52 week5.22 Last close12.28 Last change3.63%
RSI63.42 Average true range0.61 Beta1.9 Volume427.11 K
Simple moving average 20 days6.33% Simple moving average 50 days33.69% Simple moving average 200 days12.78%
Performance Data
Performance Week-4.73% Performance Month34.65% Performance Quart69.85% Performance Half10.13%
Performance Year-28.19% Performance Year-to-date99.35% Volatility daily3.51% Volatility weekly7.86%
Volatility monthly16.1% Volatility yearly55.77% Relative Volume342.21% Average Volume859.23 K
New High New Low


2019-03-12 10:45:00 | Epizyme Announces Closing of Concurrent Public Offerings and Full Exercise of Underwriter’s Option to Purchase Additional Shares

2019-03-08 12:14:36 | Does Epizyme, Inc.’s NASDAQ:EPZM CEO Salary Compare Well With Others?

2019-03-06 22:16:00 | Epizyme Announces Pricing of Concurrent Public Offerings of Common Stock and Series A Preferred Stock

2019-03-06 16:01:00 | Epizyme Announces Proposed Concurrent Public Offerings of Common Stock and Series A Preferred Stock

2019-03-05 06:30:00 | Epizyme Announces Presentations at Upcoming March Investor Conferences

2019-02-27 10:14:03 | Epizyme EPZM Reports Narrower-Than-Expected Loss in Q4

2019-02-26 18:13:32 | Edited Transcript of EPZM earnings conference call or presentation 26-Feb-19 1:30pm GMT

2019-02-26 06:30:00 | Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-19 06:30:00 | Epizyme Announces Date of Fourth Quarter and Full Year 2018 Results and Upcoming Presentation at the 8th Annual SVB Leerink Global Health Care Conference

2019-02-14 12:58:05 | 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings

2019-02-12 07:35:00 | New Research: Key Drivers of Growth for ON Semiconductor, Entegris, Universal, MarineMax, Epizyme, and Merrimack Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production

2019-01-07 18:14:11 | Epizyme to File NDA for Tazemetostat in Follicular Lymphoma

2019-01-07 08:09:51 | Why Epizyme Stock Rose ~33% on January 4

2019-01-04 16:27:00 | Why GameStop, Novavax, and Epizyme Jumped Today

2019-01-04 14:13:00 | Here's Why Epizyme's Shares Are Surging 19.6% Higher Today

2019-01-04 10:10:00 | These 4 Healthcare Stocks Are Making Moves

2019-01-04 06:30:00 | Epizyme Announces Registration Path for Tazemetostat for Follicular Lymphoma and Provides Pipeline Updates and 2019 Guidance

2018-12-19 22:44:37 | Is Epizyme Inc EPZM Going to Burn These Hedge Funds?

2018-12-18 06:30:00 | Epizyme Earns $8 Million Milestone Payment from GlaxoSmithKline for Initiation of Clinical Development for First-in-Class PRMT1 Inhibitor

2018-12-02 09:30:02 | Why Is Epizyme EPZM Down 11.9% Since Last Earnings Report?

2018-11-15 06:35:00 | Epizyme Announces Conference Call to Discuss Corporate Updates

2018-11-09 08:00:00 | Market Trends Toward New Normal in Paramount Group, Envestnet, Assurant, HubSpot, Epizyme, and Cytosorbents — Emerging Consolidated Expectations, Analyst Ratings

2018-11-05 14:20:07 | Epizyme EPZM Reports Narrower-Than-Expected Loss in Q3

2018-11-02 07:40:11 | Epizyme EPZM Reports Q3 Loss, Lags Revenue Estimates

2018-11-02 06:35:38 | Epizyme: 3Q Earnings Snapshot

2018-11-02 06:30:00 | Epizyme Reports Third Quarter 2018 Financial Results and Tazemetostat Progress

2018-10-22 05:00:00 | Epizyme Reports Positive Data on Tazemetostat in Epithelioid Sarcoma from its Phase 2 Trial Cohort at ESMO

2018-10-18 13:28:01 | What Kind Of Investor Owns Most Of Epizyme Inc NASDAQ:EPZM?

2018-10-17 07:45:00 | Research Report Identifies Oxford Immunotec Global, Ascena Retail Group, Groupon, Epizyme, Regulus Therapeutics, and B Communications with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2018-10-12 05:00:00 | Big Biotech Investors Poured $29 Million Into 2 Battered Companies

2018-10-10 06:45:00 | Epizyme to Present Updated Data on Tazemetostat from Full Phase 2 Study Cohort in Epithelioid Sarcoma at ESMO

2018-10-05 16:05:00 | Epizyme Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares

2018-10-03 07:54:54 | The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares

2018-10-02 17:00:00 | After-hours buzz: TPX, JCP & more

2018-10-02 16:01:00 | Epizyme Announces Proposed Public Offering of Common Stock

2018-09-25 10:52:02 | FDA Lifts Clinical Hold on Epizyme's Lead Candidate's Study

2018-09-24 07:45:00 | Epizyme's stock soars after FDA lifts hold on trial enrollments

2018-09-24 06:30:00 | Epizyme Announces the U.S. Food and Drug Administration Lifts Partial Clinical Hold on Tazemetostat Clinical Program

2018-08-29 07:00:00 | Epizyme to Participate in Upcoming Investor Conferences

2018-08-20 07:30:00 | Research Report Identifies Blucora, Sapiens International Corporation N.V, AxoGen, Epizyme, Nova Measuring Instruments, and Silver Standard Resources with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2018-08-03 17:34:09 | Epizyme EPZM Q2 Loss Narrows, Shares Crash 24% on Setbacks

2018-08-02 13:14:51 | Edited Transcript of EPZM earnings conference call or presentation 2-Aug-18 12:30pm GMT

2018-08-02 10:20:02 | Epizyme EPZM Reports Q2 Loss, Tops Revenue Estimates

2018-08-02 10:07:02 | Epizyme EPZM Reports Narrower-than-Expected Q2 Loss

2018-08-02 09:18:23 | Epizyme: 2Q Earnings Snapshot

2018-08-02 07:00:00 | Epizyme Reports Second Quarter 2018 Financial Results and Provides Business Updates

2018-07-31 16:44:08 | What's in Store for Epizyme EPZM This Earnings Season?

2018-07-19 07:30:00 | Epizyme Announces Date of Second Quarter 2018 Financial Results and Business Update Conference Call

2018-06-21 07:25:00 | Stock Performance Review on Exelixis and Three Other Biotech Stocks

2018-06-15 05:30:00 | Epizyme Reports Positive Updated Interim Data from Phase 2 Study of Tazemetostat in Patients With Relapsed or Refractory Follicular Lymphoma at the Congress of the European Hematology Association EHA